CD134 as target for specific drug delivery to auto-aggressive CD4+T cells in adjuvant arthritis
Arthritis Research & Therapy volume 7, Article number: R604 (2005)
T cells have an important role during the development of autoimmune diseases. In adjuvant arthritis, a model for rheumatoid arthritis, we found that the percentage of CD4+ T cells expressing the activation marker CD134 (OX40 antigen) was elevated before disease onset. Moreover, these CD134+ T cells showed a specific proliferative response to the disease-associated epitope of mycobacterial heat shock protein 60, indicating that this subset contains auto-aggressive T cells. We studied the usefulness of CD134 as a molecular target for immune intervention in arthritis by using liposomes coated with a CD134-directed monoclonal antibody as a drug targeting system. Injection of anti-CD134 liposomes subcutaneously in the hind paws of pre-arthritic rats resulted in targeting of the majority of CD4+CD134+ T cells in the popliteal lymph nodes. Furthermore, we showed that anti-CD134 liposomes bound to activated T cells were not internalized. However, drug delivery by these liposomes could be established by loading anti-CD134 liposomes with the dipalmitate-derivatized cytostatic agent 5'-fluorodeoxyuridine. These liposomes specifically inhibited the proliferation of activated CD134+ T cells in vitro, and treatment with anti-CD134 liposomes containing 5'-fluorodeoxyuridine resulted in the amelioration of adjuvant arthritis. Thus, CD134 can be used as a marker for auto-aggressive CD4+ T cells early in arthritis, and specific liposomal targeting of drugs to these cells via CD134 can be employed to downregulate disease development.
In several autoimmune diseases, for example rheumatoid arthritis, the involvement of CD4+ T cells in disease induction has been suggested . As a treatment strategy, the manipulation of CD4+ T cells by CD4-directed antibodies has therefore been studied extensively . However, because anti-CD4 therapy targets the whole CD4+ population, CD4+ T cells not related to the disease or involved in disease regulation will also be affected. Ideally, only the auto-aggressive CD4+ T cells that are involved in the disease process should be targeted. Because for many human autoimmune diseases the exact antigens recognized by these cells are not known, a therapy would be favorable that specifically targets the auto-aggressive CD4+ T cells and does not depend on the definition of the crucial auto-antigen.
Because auto-reactive CD4+ T cells become activated upon recognition of their cognate antigen in the periphery, they will be transiently marked by the expression of T cell activation markers. In this respect, CD134 (OX40 antigen) is an interesting candidate target molecule, because CD134 is expressed in vivo exclusively on activated CD4+ T cells (reviewed in ). In experimental autoimmune encephalomyelitis, a disease model for multiple sclerosis, it has been shown that CD134 is preferentially expressed on pathogenic CD4+ T cells that home to the target organ (namely the central nervous system) , and transiently marks the auto-aggressive T cells specific for myelin basic protein . Moreover, in this T cell transfer model, depletion of CD134+ T cells with an anti-CD134 immunotoxin results in the amelioration of paralytic symptoms . Interestingly, in patients with rheumatoid arthritis a high percentage of CD4+ T cells in synovial fluid express CD134 in comparison with peripheral blood T cells [6, 7], suggesting that auto-aggressive CD4+ T cells may be transiently marked by surface expression of CD134 in arthritis too.
Here, we investigated whether CD134 can be used as a target for specific drug delivery to activated auto-aggressive CD4+ T cells in arthritis. For this purpose, the rat adjuvant arthritis (AA) model was studied. In this model, a syndrome resembling rheumatoid arthritis is actively induced in Lewis rats after immunization with Mycobacterium tuberculosis (Mt) in adjuvant . We first analyzed the CD134 expression on CD4+ T cells during AA, and investigated the presence of auto-aggressive T cells within the CD134+CD4+ T cell subset. We also studied drug delivery to CD134+ T cells both in vitro and in vivo using liposomes coated with a CD134-directed monoclonal antibody (mAb) as a drug targeting system. To investigate the possibility for therapeutic intervention in arthritis, anti-CD134 liposomes were loaded with a cytostatic drug and administered early in actively induced arthritis. We show that CD134 can be used as a marker for activated auto-aggressive T cells early in AA, that targeting of these cells in vivo can be achieved with anti-CD134 liposomes, and that the course of AA could be affected with drug-containing anti-CD134 liposomes.
Materials and methods
Male inbred Lewis rats were obtained from the University of Limburg (Maastricht, The Netherlands) and were used between 7 and 10 weeks of age. The animals were kept under conventional conditions and had access to standard pelleted rat chow and acidified water ad libitum. The Utrecht University Animal Ethics Committee approved all animal experiments.
Heat-killed Mt, strain H37RA, was obtained from Difco Laboratories (Detroit, Michigan, USA). For immunization, Mt was suspended in incomplete Freund's adjuvant (Difco Laboratories). Peptides Mt HSP60176–190 (EESNTFGLQLELTEG; one-letter amino acid codes) (HSP60 stands for heat shock protein 60), Mt HSP60211–225 (AVLEDPYILLVSSKV) and OVA323–339 (ISQAVHAAHAEINEAGR) (OVA stands for Ovalbumin) were obtained from Isogen Bioscience (Maarssen, The Netherlands).
mAbs and second-step reagents
The anti-CD134 (OX40) and anti-CD25 (OX39) hybridomas were obtained from the ECACC (Salisbury, UK) . The 12CA5 hybridoma producing IgG2b isotype control mAb was kindly provided by Dr GJ Strous (Department of Cell Biology and Institute of Biomembranes, University Medical Center, Utrecht, The Netherlands). mAbs were isolated from hybridoma supernatant by affinity chromatography with GammaBind Plus Sepharose (Roche Pharmacia, Uppsala, Sweden). For ease of flow cytometric detection, some purified mAbs were biotinylated with D-biotinoyl-ε-aminohexanoic acid-N-hydroxy-succinimide ester (Roche Molecular Biochemicals, Basel, Switzerland). Fluorescein isothiocyanate (FITC)-conjugated anti-CD4 (OX35) and anti-CD45RA (OX33), phycoerythrin (PE)-conjugated goat-anti-mouse immunoglobulin, PE-conjugated streptavidin, peridinin chlorophyll protein (PerCP)-conjugated anti-T-cell antigen receptor (anti-TCR)-αβ (R73) and IgG1 isotype control (A112), and allophycocyanin-conjugated streptavidin were purchased from BD Pharmingen (San Diego, California, USA).
Culture of rat CD4+T cell clone A2b
The isolation, maintenance, and properties of rat CD4+ T cell clone A2b have been described previously . The arthritogenic T cell clone A2b recognizes the 180 to 188 epitope of Mycobacterium tuberculosis HSP60 . Cells were cultured in medium (Iscove's modified Dulbecco's medium (Invitrogen, Merelbeke, Belgium), supplemented with L-glutamine (2 mM), 2-mercaptoethanol (50 μM), penicillin (50 U/ml) and streptomycin (50 μg/ml)) with 2% heat-inactivated normal rat serum.
Induction of AA
Rats were injected intradermally with 100 μl of Mt in incomplete Freund's adjuvant at the base of the tail. For studying cell-surface marker expression, CD4+ subset specificity during AA and liposome binding in vivo, 10 mg/ml Mt was used. For AA treatment studies, rats were immunized with 5 mg/ml Mt (yielding 100% disease incidence, but lower maximum disease scores in comparison with 10 mg/ml Mt). Rats were weighed and examined for clinical signs of arthritis in a semi-blinded set-up. Severity of arthritis was scored by grading each paw from 0 to 4 based on erythema, swelling and immobility of the joints, resulting in a maximum score of 16 per animal .
Ex vivoanalysis of cell-surface marker expression
Before Mt immunization or 7, 10, 14, 21 or 35 days afterwards, rats were killed and popliteal lymph nodes (PLN), inguinal lymph nodes (ILN), spleen, and peripheral blood were isolated. Single-cell suspensions were prepared by mechanically forcing the organs through a 70 μm mesh; erythrocytes were removed from the splenocyte and blood suspensions by Ficoll-Isopaque gradient centrifugation. Cells (2 × 105 per sample) were labeled with anti-CD134 for 30 min on ice, followed by incubation with PE-conjugated goat anti-mouse immunoglobulin and subsequently with anti-CD4-FITC. The cells were incubated and washed (between each labeling step) in blocking buffer (PBS (Cambrex Bio Science, Verviers, Belgium) containing 4% heat-inactivated rat serum, 1% fraction V BSA (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) and 0.1% NaN3). Finally, cells were washed in PBS, fixed in 2% paraformaldehyde and stored at 4°C in the dark. Cell-associated fluorescence was analyzed within 10 days on a FACSCalibur using Cell Quest software (Becton Dickinson, Brussels, Belgium).
Cell sorting and ex vivo proliferation of CD4+T cell subsets
At 7 and 10 days after Mt immunization, PLN, ILN, and spleens of 10 to 15 rats were isolated and each organ type was pooled. Single-cell suspensions were prepared as described above. Cells were washed and incubated in PBS containing 4% heat-inactivated rat serum, and stained with anti-CD134-biotin/streptavidin-allophycocyanin and anti-CD4-FITC. CD4+, CD4+CD134- and CD4+CD134+ cells were sorted with a FACS Vantage and Cell Quest software (Becton Dickinson), resulting in fractions that were 87 to 97% pure.
Sorted cells were washed and incubated for 72 hours in medium with 2% heat-inactivated normal rat serum in flat-bottomed 96-well plates (Corning-Costar, Schiphol, The Netherlands) at 5 × 104 cells per well in the presence of 30 Gy-irradiated thymocytes as antigen-presenting cells (APC) (106 cells per well) and concanavalin A (Con A; 2.5 μg/ml) or antigen (20 μg/ml Mt HSP60176–190, 20 μg/ml Mt HSP60211–225). Finally, cells were pulsed for 18 to 20 hours with [3H]thymidine, 0.4 μCi per well (specific radioactivity 1 Ci/mmol; Amersham Biosciences, Roosendaal, The Netherlands), after which [3H]thymidine incorporation was measured. Results are presented as the mean stimulation index (SI, defined as [3H]thymidine incorporation in the presence of antigen or Con A divided by [3H]thymidine incorporation in the absence of antigen or Con A) of triplicate wells. For logistic reasons, ILN single-cell suspensions were kept overnight on ice and were washed, stained and sorted on the following day.
Preparation of (mAb-coupled) PEG-liposomes
Liposomes were composed of egg phosphatidylcholine, cholesterol, poly(ethyleneglycol)2000-distearoylphosphatidylethanolamine (PEG2000-DSPE) and maleimide-PEG2000-DSPE in a molar ratio of 2:1:0.075:0.075. Egg phosphatidylcholine was kindly provided by Lipoid (Ludwigshafen, Germany), PEG2000-DSPE was purchased from Avanti Polar Lipids (Birmingham, Alabama, USA), cholesterol from Sigma-Aldrich Chemie, and Maleimide-PEG2000-DSPE from Shearwater Polymers (Huntsville, Alabama, USA). Liposomes used for investigating liposome binding in vivo contained 0.1 mol% 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD; Molecular Probes Europe, Leiden, The Netherlands). Liposomes used for investigating in vitro binding and internalization contained 0.1 mol% Texas red-phosphatidylethanolamine (Molecular Probes Europe). Liposomes used for studying drug delivery in vitro and for the treatment of AA contained 2 mol% 5'-fluoro-2'-deoxyuridine dipalmitate (FUdR-dP; that is, 0.06 mol FudR-dP per 3 mol main lipid constituents) (synthesized as described previously ).
Lipids (and FUdR-dP or DiD) were dissolved in chloroform/methanol (9:1) and mixed. A lipid film was prepared through rotary evaporation under vacuum and dried under nitrogen. The lipids were hydrated with HN buffer (4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid (HEPES) and 135 mM NaCl) at pH 6.7. The resulting vesicles were sized by repeated extrusion through 100 nm polycarbonate filters. Particle size and size distribution were determined by dynamic laser light scattering with an Autosizer 4700 Spectrometer (Malvern Instruments, Malvern, Worcestershire, UK). Liposome preparations had a mean particle diameter ranging from 100 to 200 nm (polydispersity between 0.1 and 0.2). Typically, the mean liposomal diameter varied by less than 20% within any given experiment. The anti-CD134 or IgG2b isotype control mAbs were coupled to liposomes by a thiol-maleimide method described previously . In brief, free thiol groups were introduced in the mAbs using the heterobifunctional reagent N-succinimidyl-S-acetylthioacetate (SATA; Sigma-Aldrich Chemie). Free SATA was separated from the derivatized mAbs by gel permeation chromatography, resulting in ATA-derivatized mAbs dissolved in HN buffer at pH 7.4. mAbs with reactive thiol groups, induced by deacetylating the ATA-protein, were incubated with liposomes at 4°C overnight at a ratio of 0.05 to 0.1 mg of mAbs per μmol lipid. N-ethylmaleimide (8 mM in HN buffer, pH 7.4) was added to cap unreacted thiol groups. Unconjugated mAbs were removed by gel-permeation chromatography or by centrifugation at 100,000 g. The liposomal protein content was determined as described previously . Liposomes contained 25 to 125 μg of mAbs per μmol of lipid. Typically, the mAb content of the different liposome preparations within any given experiment varied by less than 20%.
Liposome binding to CD4+ T cells in vivo
On day 7 after Mt immunization, rats received saline or 5 μmol (lipid) DiD-labeled liposomes subcutaneously (s.c.) in each hind paw. After 30 min the rats were killed, and the PLN, ILN, and spleens were isolated. Single-cell suspensions were prepared as described above. Subsequently, cells were stained with anti-CD4-FITC, anti-CD134-biotin/streptavidin-PE and anti-TCR-αβ-PerCP, or with anti-CD45RA-FITC, anti-CD134-biotin/streptavidin-PE and anti-TCR-αβ-PerCP. Cell-associated fluorescence was measured by flow cytometry.
Liposomal drug delivery to T cells in vitro
A2b T cells were activated in vitro to induce CD134 expression by stimulation overnight with 2.5 μg/ml Con A (Sigma-Aldrich Chemie) in the presence of 30 Gy-irradiated Lewis thymocytes as APC (ratio of T cells to APC = 1:25). Alternatively, a spleen cell suspension (at 2 × 105 cells/ml) was stimulated for 3 days with 2.5 μg/ml Con A to induce CD134 expression on splenic T cells. Next, viable cells were collected from the culture by Ficoll-Isopaque gradient centrifugation and transferred to round-bottomed 96-well plates at 105 cells per sample.
For studying anti-CD134 liposome binding to T cells in vitro by flow cytometry, A2b cells were incubated with 5 nmol (lipid) of anti-CD134 liposomes or IgG2b isotype control liposomes, or anti-CD134 mAb or IgG2b isotype control mAb for 30 min on ice. Cells were then washed and incubated on ice with FITC-conjugated goat anti-mouse immunoglobulin to label the cell-bound mAbs or liposomes. Finally, cell-associated fluorescence was measured. For analysis of the interaction of CD4+ T cells and liposomes by confocal microscopy, activated A2b cells were incubated with 50 nmol of the different liposomal formulations in medium for 30 min on ice, washed and cultured in medium with 2% heat-inactivated normal rat serum at 37°C in 5% CO2. Activated spleen cells were incubated with 100 nmol of liposomes. At the indicated time points, cell-associated fluorescence was assessed.
For assessment of in vitro drug delivery by anti-CD134 liposomes, activated A2b cells were incubated at 37°C in 5% CO2 without or with 1 nmol (lipid) of the different liposomal formulations per well or with an equal concentration (100 nM) of free FUdR (Sigma-Aldrich Chemie) in 200 μl of medium without serum. After 30 min, cells were washed three times in medium and cultured for 48 hours in 200 μl of conditioned medium (medium supplemented with 10% heat-inactivated fetal calf serum (Bodinco, Alkmaar, The Netherlands), 10% culture supernatant of the EL-4 lymphoma (containing murine IL-2) and 1% non-essential amino acids (Invitrogen)). Finally, cells were pulsed for 18 to 20 hours with [3H]thymidine as described above, after which [3H]thymidine incorporation was measured. Results are expressed as the mean percentage of inhibition of proliferation of duplicate cultures relative to the incubation without liposomes (defined as 0%).
Treatment of AA with liposomes and ex vivoproliferation assay of LN cells after liposomal treatment
AA was induced in Lewis rats as described above. Rats received 5 μmol of the different liposome formulations s.c. in each hind paw or HN buffer (see below) as a control on days 3 and 7 or on days 3, 7, and 10 after Mt immunization. Rats were followed for arthritis development as described above.
Proliferation of lymphocytes from liposome-treated animals was measured in quadruple cultures of 2 × 105 cells per well without additional APC. Cells were cultured in 96-well flat-bottomed plates in 200 μl of medium containing 2% heat-inactivated normal rat serum in the absence or presence of antigen (20 μg/ml Mt HSP60176–190 or 20 μg/ml OVA232–339) or Con A (2.5 μg/ml). After 72 hours, cells were pulsed for 18 to 20 hours with [3H]thymidine as described above, after which [3H]thymidine incorporation was measured.
The statistical significance of differences was evaluated with GraphPad Prism 3.02 (GraphPad Software, San Diego, California, USA). For statistical analysis of CD134 expression in vivo and liposomal drug delivery in vitro, a one-way analysis of variance with Dunnett's post-hoc test was used. For analysis of differences in the development of AA, a Mann-Whitney test was used for arthritis scores and an unpaired Student's t-test for body weight.
Expression of CD134 on CD4+T cells during AA
To study the expression of CD134 and CD4 during AA, Lewis rats were immunized with Mt in adjuvant. The first signs of inflammation of the paw joints were observed between days 10 and 14, and the disease reached maximum severity at days 20 to 22. After this, inflammation of paw joints gradually decreased and resolved macroscopically at days 35 to 40. At several time points during AA development, the PLN (which drain the foot and ankle joints), the ILN (which drain the Mt immunization site), the spleen, and blood were isolated and examined by flow cytometry.
Seven days after Mt immunization, before the clinical onset of AA, the percentage of CD134+ T cells was increased both in the PLN and ILN in comparison with naive animals (day 0; Fig. 1a,b). In the ILN this percentage remained elevated throughout the active disease phase between days 10 and 30 (Fig. 1b). In the PLN a decrease in the percentage of CD134+ T cells on days 10 and 14 was observed. On day 21 the percentage of CD134+CD4+ cells was found to increase again (Fig. 1a). The total cell number in the PLN at day 7 (8.5 × 106 ± 1.6 × 106, mean ± SEM) and day 10 (8.3 × 106 ± 2.7 × 106) was comparable, as well as the percentage of CD4+ cells (percentage of live lymphocytes; Fig. 1d). This indicated that the absolute number of CD134+CD4+ T cells decreased during the interval from day 7 to day 10. In the spleen, the main increase in the percentage of CD134-expressing T cells was observed at about day 14 (Fig. 1c). In peripheral blood, no changes were detected in the percentage of CD134+ cells during the onset of AA (data not shown). We did not observe a significant increase in the percentage of CD4+ cells during AA in any of the organs tested (Fig. 1d–f). The data shown in Fig. 1 represent a compilation of four separate experiments, in which all rats were immunized on one day and flow cytometric analysis was performed on separate days. Another experiment in which rats were immunized on separate days (n = 4 rats per time point), and flow cytometric analysis was performed on one day, yielded similar results (data not shown).
Specific responsiveness of CD134+T cells to the disease-associated epitope of Mt HSP60
Previously, it has been shown that a CD4+ T cell clone (clone A2b ), derived from a Lewis rat after Mt immunization and capable of transferring arthritis to naive rats, recognized a T cell epitope present in the 176–190 region of Mt HSP60 (Mt HSP60176–190) . To investigate whether CD134+ T cells early in AA were potentially arthritogenic, we tested CD134+CD4+ T cells isolated at days 7 and 10 after Mt immunization – that is, just before the onset of clinical disease – for their proliferative response to peptide Mt HSP60176–190. The results for day 10 are presented in Fig. 2. PLN-derived CD4+ cells showed a low proliferative response to the disease-associated peptide (SI ≈ 3; Fig. 2). When the CD4+ population was divided into CD134+ and CD134- fractions, the Mt HSP60176–190 response of the CD4+ cells was entirely attributable to the CD134+ cells, as these cells showed a high proliferative activity to Mt HSP60176–190, whereas this response was absent in the CD134- population (SI < 2). Similar results were found for the CD4+ subsets isolated from ILN and spleen (Fig. 2). The isolated CD134+CD4+ cells also showed a response to another mycobacterial HSP60 epitope, peptide 211–225, which has been reported not to be related to AA . However, this response was much lower than the Mt HSP60176–190 response (Fig. 2). Data obtained at day 7 (data not shown) and day 10 were similar. Thus, the CD134+ T cell population found early in AA was enriched for activated auto-aggressive CD4+ T cells, as shown by the specific response to the disease-associated epitope Mt HSP60176–190.
Specific targeting to CD134+T cells in draining lymph nodes with anti-CD134 liposomes
For delivery of modulating compounds to the potentially arthritogenic CD134+ T cells, we selected a mAb-targeted liposomal system. To investigate whether the CD134+ CD4+ T cells in the draining LN could be targeted in vivo, fluorescent anti-CD134 liposomes were injected s.c. in the hind paws of rats on day 7 after Mt immunization. After 30 min, rats were killed, and the T cells in the joint-draining PLN, the immunization site-draining ILN and spleen were studied for CD134 expression and for the presence of cell-bound liposomes by flow cytometry. In the PLN, 10.7% of the cells were found to be both CD4+ and CD134+, whereas 7.5% of the cells had bound anti-CD134 liposomes and were CD4+ (Fig. 3a). Competitive counterstaining of liposome+CD4+ cells with anti-CD134 mAbs showed that virtually all these cells were indeed CD134+ (Fig. 3b). This implies that the vast majority of CD134+ T cells in the PLN was targeted. In addition, also CD4- cells were targeted in the PLN (Fig. 3a). In this case, however, binding of both anti-CD134- and isotype control liposomes was comparable and these cells were determined to be CD45RA+ B cells (Fig. 3c). Because B cells do not express CD134, the anti-CD134 binding could not be due to CD134 binding. The similar staining pattern of isotype control liposomes and anti-CD134 liposomes on B cells suggested that this binding was due to Fc-mediated binding (because whole mAb was used to coat liposomes). In the ILN or the spleen virtually no CD134+ CD4+ T cells were targeted by anti-CD134 liposomes administered s.c. in the paw (Fig. 3a).
Drug delivery to CD134+ T cells in vitrousing anti-CD134 liposomes containing the dipalmitate-anchored cytostatic agent FUdR
The fate of anti-CD134 liposomes after binding to activated CD4+ T cells was studied in vitro by incubation of activated T cells of clone A2b with anti-CD134 liposomes. Activated CD134+ A2b T cells were shown to specifically bind anti-CD134 liposomes (Fig. 4a). Interestingly, although resting A2b cells seemed CD134- after conventional mAb staining, anti-CD134 liposomes did bind to these cells to a small extent.
Using confocal microscopy, anti-CD134 liposomes were shown to bind specifically to activated CD4+ T cells in a diffuse pattern; that is, spread out over the plasma membrane (Fig. 4b). When cells that had bound liposomes were incubated at 37°C, the staining pattern of anti-CD134 liposomes changed from diffuse to a more focal pattern after 2 hours of culture at 37°C (Fig. 4b, 2 hours). However, no internalization of anti-CD134 liposomes was observed at any of the time points evaluated. This was also observed with Con A-activated splenic T cells (data not shown). As a positive control for liposome internalization, liposomes targeting CD25, the α-subunit of the IL-2 receptor, which is also expressed on activated CD4+ T cells, were used (Fig. 4b, 4 hours). Furthermore, activated CD4+ T cells were able to internalize anti-CD134 mAbs (and anti-CD25 mAbs) within 2 hours of binding (data not shown). This indicated that although the CD134 receptor itself was internalized, cell-bound anti-CD134 liposomes were not internalized by the targeted T cells.
Our finding that anti-CD134 liposomes were not internalized by the target T cells had major implications for the strategy of drug delivery. We decided to use the mechanism of lipid-coupled drug transfer between membranes to achieve intracellular drug delivery. The lipid-derivatized cytostatic agent FUdR-dP was used as a model drug . Activated, CD134+ rat T cells of clone A2b were found to be very sensitive to free FUdR (90% growth inhibition with 100 nM FUdR) when FUdR was continuously present during culture for 48 hours. However, when the cells were incubated for only 30 min with free FUdR and then washed to remove extracellular FUdR, no significant growth inhibition was detected during subsequent culture (Table 1). When the equivalent amount of FUdR was present in 1 nmol anti-CD134 liposomes (anti-CD134-FUdR-dP liposomes), which were incubated for 30 min with the cells, the proliferation of activated A2b cells was inhibited by more than 30% (Table 1). Incubation of activated T cells with anti-CD134 liposomes without FUdR-dP or with non-targeted FUdR-dP liposomes did not significantly affect the proliferation of the cells (P > 0.05; Table 1).
Modulation of AA by treatment with drug-containing anti-CD134 liposomes
Next, we investigated whether local targeting to CD134+ T cells in the joint-draining PLN would affect the course of actively induced arthritis in the AA model. Rats were injected with the different liposomal formulations on days 3 and 7 after Mt immunization and were followed for arthritis development. Injection of anti-CD134-FUdR-dP liposomes resulted in less severe disease development than in rats injected with anti-CD134 liposomes without FUdR-dP (Fig. 5a). This effect was increased by the administration of anti-CD134-FudR-dP liposomes on three occasions (Fig. 5b). The improved well-being of the anti-CD134-FUdR-dP liposome-treated rats was also reflected in a faster recovery of weight (Fig. 5a). The isotype control FUdR-dP liposomes also seemed to affect the progression of AA, although anti-CD134-FUdR-dP liposomes were more effective. No difference in AA scores was found between rats treated with empty anti-CD134 liposomes and rats treated with empty, bare liposomes (data not shown).
The modulation of the course of AA after treatment with anti-CD134-FUdR-dP liposomes was correlated with a decreased proliferative response to Mt HSP60176–190 of joint-draining PLN cells isolated at day 42 (Fig. 5c). This is indicative of successful targeting and deletion of Mt HSP60176–190-reactive, CD134+ T cells in vivo.
In the present study we investigated whether CD134 can be used as a (transient) marker for targeting auto-aggressive CD4+ T cells in actively induced experimental arthritis. Before the onset of clinical arthritis, an elevated percentage of CD134+ CD4+ T cells was found in the PLN, which drain the foot and ankle joints, and in the ILN, which drain the Mt immunization site. In the ILN, this percentage remained elevated throughout the active disease phase, indicating a continuous activation of T cells, probably because of the presence of an Mt depot at the base of the tail. However, in the PLN the percentage and absolute number of CD134+ T cells were decreased at days 10 and 14 after immunization in comparison with the initial elevation on day 7. In this arthritis model, the first signs of clinical disease become manifest between days 10 and 14, and at about this time T cells start to infiltrate the joints . The present data therefore suggest that early in AA, CD134+ T cells, after activation in the PLN, can migrate to the joints, where they subsequently become involved in joint inflammation. The second increase in the percentage of CD134-expressing T cells in the PLN on days 21 and 35 could reflect the recirculation or generation of activated auto-aggressive T cells, or the emergence of an activated regulatory population.
The presence of arthritogenic cells in the CD134+ subset of CD4+ T cells isolated from pre-arthritic rats was deduced from the high proliferative response to the Mt HSP60176–190 peptide, which was previously linked to the induction of AA . However, the CD134+ T cell subset also includes activated (auto-aggressive) T cells with a different specificity. The low but evident response of isolated CD4+CD134+ cells to Mt HSP60211–225, which was reported not to be related to AA , indeed indicated that a part of the CD134+ T cells was not activated in relation to clinical disease but responded to other epitopes present in the immunization mix. This underlines the fact that, although CD134 may be used to select for activated pathogenic CD4+ T cells in an autoimmune setting, this molecule is primarily a marker for activated CD4+ T cells in general [18–20]. Nevertheless, by using CD134 as marker for targeting, we expected to affect all recently activated auto-aggressive CD4+ T cells present at the time of targeting, including arthritogenic T cells with a different specificity from that of Mt HSP60176–190. The preferential expression of CD134 on synovial fluid CD4+ T cells from patients with rheumatoid arthritis, as has been demonstrated by others [6, 7, 21], indicates that also in humans auto-reactive T cells might be (transiently) marked by CD134. Because CD134 ligand expression has been demonstrated both on vascular endothelial cells [22, 23] and in synovial tissue of rheumatoid arthritis patients , the recruitment and in situ restimulation of activated T cells through CD134 possibly contributes to the inflammatory process in arthritis. Indeed, in a mouse collagen-induced arthritis model, treatment with a mAb blocking anti-CD134 ligand did inhibit disease development .
To explore the possibility for modulating auto-aggressive T cells in arthritis, we examined the potential of drug targeting directly to CD134+ T cells in AA by using liposomes as drug carriers. To study the ability of anti-CD134 liposomes to reach the potentially auto-reactive CD134+ T cells in vivo, the active disease model was employed, because this would allow targeting of the target T cells during priming in situ; that is, in the secondary lymphoid organs. When anti-CD134 liposomes were injected s.c. in the hind paws, the majority of the CD4+CD134+ T cells in the joint-draining PLN could indeed be targeted. The non-T cells in the PLN that were found to bind both anti-CD134 liposomes and isotype control liposomes were determined as being B cells that most probably bound the liposomes in a Fc-mediated fashion.
Activated CD134+ T cells targeted by anti-CD134 liposomes in vitro did not internalize the cell-bound liposomes. This lack of internalization determined the strategy of drug delivery. We here employed the mechanism of lipid-coupled drug transfer between membranes to achieve intracellular drug delivery. When anti-CD134 liposomes carried the lipid-coupled cytostatic agent FUdR as a model drug, a 30% inhibition of proliferation of activated CD134+ T cells was observed in vitro. This inhibitory effect on the proliferation of CD134+ T cells in vitro was correlated with a moderate suppression of AA in rats treated with anti-CD134-FUdR-dP liposomes. The effect of these liposomes on AA development was supported by a downregulation of the disease-associated Mt HSP60176–190 response in the PLN of anti-CD134-FUdR-dP liposome-treated animals.
The effect of isotype control-FUdR-dP on clinical disease might be due to their association with B cells in vivo, probably through binding to Fc receptors . Although B cells have not been described as having a crucial role in the development of AA , contrary to collagen-induced arthritis in mice, for example , these cells can function as APC and as such may affect the response of auto-aggressive T cells in vivo. Optimizing the therapeutic entity, for example by coupling anti-CD134 Fab fragments to the liposomal carrier instead of the entire anti-CD134 antibody, would circumvent B cell targeting.
It has recently been shown that CD4+CD25+ regulatory T cells involved in the control of autoimmunity  can express CD134 [28–30]. Although CD134+ regulatory T cells may go through a proliferative phase in vivo [31, 32], in general these cells display a hypoproliferative phenotype in vitro as well as in vivo . Because cytostatic agents act primarily on proliferating cells, it is possible that by employing FUdR-dP-containing anti-CD134 liposomes we largely preserved this regulatory T cell subset.
We show here that CD134 can be used as a marker for recently activated CD4+ T cells with auto-aggressive potential in arthritis, and that anti-CD134 liposomes can be used to target drugs directly to these T cells. Thus, anti-CD134 liposomes represent an attractive method for the development of therapies aiming at the modulation of auto-aggressive T cells for intervention in autoimmune diseases.
= adjuvant arthritis
= antigen-presenting cells
- Con A:
= concanavalin A
- DiD = 1:
1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt
= fluorescein isothiocyanate
= 5'-fluoro-2'-deoxyuridine (dipalmitate)
= heat shock protein
= inguinal lymph nodes
= monoclonal antibody
= Mycobacterium tuberculosis
= phosphate-buffered saline
= peridinin chlorophyll protein
= popliteal lymph nodes
= stimulation index
= T-cell antigen receptor.
Panayi GS, Corrigall VM, Pitzalis C: Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am. 2001, 27: 317-334.
Schulze-Koops H, Lipsky PE: Anti-CD4 monoclonal antibody therapy in human autoimmune diseases. Curr Dir Autoimmun. 2000, 2: 24-49.
Sugamura K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004, 4: 420-431. 10.1038/nri1371.
Weinberg AD, Wallin JJ, Jones RE, Sullivan TJ, Bourdette DN, Vandenbark AA, Offner H: Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol. 1994, 152: 4712-4721.
Weinberg AD, Lemon M, Jones AJ, Vainiene M, Celnik B, Buenafe AC, Culbertson N, Bakke A, Vandenbark AA, Offner H: OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J Neurosci Res. 1996, 43: 42-49. 10.1002/jnr.490430105.
Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, Davey M, Palida F, Godfrey W, Engleman E, et al: Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med. 1996, 2: 183-189. 10.1038/nm0296-183.
Brugnoni D, Bettinardi A, Malacarne F, Airo P, Cattaneo R: CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis. Br J Rheumatol. 1998, 37: 584-585. 10.1093/rheumatology/37.5.584.
Pearson CM: Development of arthritis, periarthritis and periostitis in rats given adjuvant. Proc Soc Exp Biol Med. 1956, 91: 95-101.
Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, Puklavec M, Williams AF: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987, 24: 1281-1290. 10.1016/0161-5890(87)90122-2.
Ben-Nun A, Wekerle H, Cohen IR: The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol. 1981, 11: 195-199.
van Eden W, Thole JE, van der Zee R, Noordzij A, van Embden JD, Hensen EJ, Cohen IR: Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature. 1988, 331: 171-173. 10.1038/331171a0.
Wood FD, Pearson CM, Tanaka A: Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats. Int Arch Allergy Appl Immunol. 1969, 35: 456-467.
Koning GA, Morselt HW, Velinova MJ, Donga J, Gorter A, Allen TM, Zalipsky S, Kamps JA, Scherphof GL: Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta. 1999, 1420: 153-167.
Peterson GL: A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977, 83: 346-356. 10.1016/0003-2697(77)90043-4.
Holoshitz J, Matitiau A, Cohen IR: Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. J Clin Invest. 1984, 73: 211-215.
Anderton SM, van der Zee R, Prakken B, Noordzij A, van Eden W: Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J Exp Med. 1995, 181: 943-952. 10.1084/jem.181.3.943.
Issekutz TB, Issekutz AC: T lymphocyte migration to arthritic joints and dermal inflammation in the rat: differing migration patterns and the involvement of VLA-4. Clin Immunol Immunopathol. 1991, 61: 436-447.
Gramaglia I, Weinberg AD, Lemon M, Croft M: Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol. 1998, 161: 6510-6517.
Maxwell JR, Weinberg A, Prell RA, Vella AT: Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol. 2000, 164: 107-112.
Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: Ox40 promotes Bcl-xl and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001, 15: 445-455. 10.1016/S1074-7613(01)00191-1.
Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, Yagita H, Okumura K: Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol. 2000, 30: 2815-2823. 10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-#.
Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, Imamura S, Uchiyama T: The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996, 183: 2185-2195. 10.1084/jem.183.5.2185.
Souza HS, Elia CC, Spencer J, MacDonald TT: Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999, 45: 856-863.
Phillips NE, Parker DC: Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol. 1984, 132: 627-632.
Taurog JD, Sandberg GP, Mahowald ML: The cellular basis of adjuvant arthritis. II. Characterization of the cells mediating passive transfer. Cell Immunol. 1983, 80: 198-204. 10.1016/0008-8749(83)90106-5.
Durie FH, Fava RA, Noelle RJ: Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol. 1994, 73: 11-18. 10.1006/clin.1994.1164.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.
McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002, 16: 311-323. 10.1016/S1074-7613(02)00280-7.
Stephens LA, Barclay AN, Mason D: Phenotypic characterization of regulatory CD4+CD25+ T cells in rats. Int Immunol. 2004, 16: 365-375. 10.1093/intimm/dxh033.
Nolte-'t Hoen EN, Wagenaar-Hilbers JP, Boot EP, Lin CH, Arkesteijn GJ, van Eden W, Taams LS, Wauben MH: Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation. Eur J Immunol. 2004, 34: 3016-3027. 10.1002/eji.200324725.
Fisson S, Darrasse-Jeze G, Litvinova E, Septier F, Klatzmann D, Liblau R, Salomon BL: Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med. 2003, 198: 737-746. 10.1084/jem.20030686.
Klein L, Khazaie K, von Boehmer H: In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A. 2003, 100: 8886-8891. 10.1073/pnas.1533365100.
Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A: Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. Nat Immunol. 2002, 3: 33-41. 10.1038/ni743.
We thank Dr Ger Arkesteijn for technical assistance with cell sorting, Ing. Louis van Bloois for technical assistance with preparing liposomes, Ing. Peter J van Kooten and Ing. Mayken CJT Grosfeld-Stulemeijer for technical assistance in production and purification of mAbs, and Dr Martijn A Nolte for valuable advice. The research described in this study is part of the UNYPHAR project, a research network between Yamanouchi Europe BV and the Universities of Groningen, Leiden, and Utrecht.
The author(s) declare that they have no competing interests.
EB participated in designing performing the experiments and prepared the manuscript. GK participated in, and supervised, the liposome preparations. GS participated in the design and coordination of the study, and in the interpretion of the results. JWH carried out immunological experiments and participated in the interpretation of the results. WVE participated in the design of the study and in its coordination. LE participated in the experiments, statistical analysis and interpretation of the results. MW supervised the design and execution of the study, and drafted the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Boot, E.P., Koning, G.A., Storm, G. et al. CD134 as target for specific drug delivery to auto-aggressive CD4+T cells in adjuvant arthritis. Arthritis Res Ther 7, R604 (2005). https://doi.org/10.1186/ar1722